Zinc, Vitamin C, Beta-Carotene and Copper: study protocols
5 study groups took Zinc together with Vitamin C, Beta-Carotene and Copper. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Zinc
5 study groups in 3 studies say how much Zinc participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 50 mg to 100 mg, 80% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg or less | 1 |
| 25 mg to 50 mg | 0 |
| 50 mg to 100 mg | 4 |
Dose per serving from research: Vitamin C
5 study groups in 3 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 100% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 5 |
Dose per serving from research: Beta-Carotene
5 study groups in 3 studies say how much Beta-Carotene participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 100% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg to 25 mg | 5 |
Commonly used together
5 of 5 study groups took Zinc, Vitamin C, Beta-Carotene and Copper with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin E | 5 |
5 study groups
| Study | ||||||
|---|---|---|---|---|---|---|
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · combination of antioxidants and zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 500 mg | 15 mg | 2 mg | 2409 days | — |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 500 mg | 15 mg | 2 mg | 8 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 80 mg | 500 mg | 15 mg | 2 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 80 mg | 500 mg | 15 mg | 2 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 25 mg | 500 mg | 15 mg | — | 5 years | — |